IN THE CLAIMS:

Please cancel claims 1, 10, 12, 15, 17, 27 and 28 without prejudice or disclaimer.

Please amend claims 2-9, 11, 18-26 and 29-34 as follows:

Claim 2, line 1: Change "compound" to -- method -- and Change "1," to -- 11, --.

Claim 3, line 1: Change "compound" to -- method -- and Change "1," to -- 11, --.

Claim 4, line 1: Change "compound" to -- method -- and Change "1," to -- 11, --.

Claim 5, line 1: Change "compound" to -- method -- and Change "1," to -- 11, --.

Change "1," to -- 11, --.

Claim 7, line 1: / Change compound to -- method --.

Claim 8, line 1: phange "compound" to -- method --.

9. (Amended.) A [compound] method of claim [1] 11, wherein said compound is:

gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-methoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;

europium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-(4-methoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;



iron(III) complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-(4-methoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;

[bismuth complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-methoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;]

gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-5-(4-methoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;

gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-[4-(4-methoxybenzyloxy)benzyl]undecanedioic acid or a physiologically acceptable salt thereof;

gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-benzylundecanedioic acid or a physiologically acceptable salt thereof;

ytterbium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-benzylundecanedioic acid or a physiologically acceptable salt thereof;

gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-benzyloxymethylundecanedioic acid or a physiologically acceptable salt thereof;

gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-(4-carboxymethoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;

gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-(4-ethoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;

europium complex of 3,6,9 triaza-3,6,9-tris(carboxy-methyl)-4-(4-ethoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;

iron complex of 3,6,9-triaza 3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;

gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-(4-butoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;

europium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-(4-butoxybenzyl)undecanedioic acid or a physiologic-ally acceptable salt thereof;

iron complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-butoxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;

gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-(4-benzyloxybenzyl) undecanedioic acid or a physiologically acceptable salt thereof;

europium complex of 3,6,9-triaza-3,6,9-tris(carboxy-methyl)-4-(4-benzyloxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof;

iron complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-benzyloxybenzyl)undecanedioic acid or a physiologically acceptable salt thereof.

11. (Amended.) A method of enhancing an NMR image comprising administering to a patient a compound of [claim 1, wherein] the formula

<u>wherein</u>

 $\underline{Z^1}$ and $\underline{Z^2}$ in each case, independently, are each $\underline{-(CH_2)_m - (C_6H_4)_q - (O)_k - (CH_2)_n - (C_6H_4)_1 - (O)_r - R},$ wherein

m and n, independently, are each 0-20,

k, 1, q and r are each, independently, 0 or 1,

R is H, C_1 - C_6 -alkyl, OR^1 -substituted C_1 - C_6 -alkyl or CH_3 COOR 1 ,

 R^1 is H, C_1 - C_6 -alkyl or benzyl; and

is a hydrogen atom and/or a metal ion equivalent of an element of atomic number 21-29, 42, 44 or 58-70;

<u>X</u>

and

SCH 1412

(I),

- 4 -

2001 13

a pharmaceutically acceptable carrier;

with the provisos that:

at least two X groups represent a metal ion <u>equivalent</u> of atomic number 21-29, 42, 44 or 58-70;

one of the substituents Z¹ and Z² is hydrogen and the other is not hydrogen;

when n and l are each 0, then k and r are not each simultaneously 1;

 $-(0)_r$ -R is not -OH; and


 $\frac{Z^{1} \text{ and } Z^{2} \text{ are not } -CH_{2}-C_{6}H_{4}-O-CH_{2}-COOCH_{2}C_{6}H_{5} \text{ or } -CH_{2}-C_{6}H_{4}-O-(CH_{2})_{5}-COOCH_{2}C_{6}H_{5};}$

or/a physiologically acceptable salt thereof with an inorganic and/or-organic base, an amino acid-or-an-amino-acid-amide.

- Claim 18, line 1: Charge "compound" to -- method -- and Change "1," to -- 11, --.
- Claim 20, line 1: Change "compound" to -- method -- and thange "1," to -- 11, --.
- Claim 21, line 1: Change "compound" to -- method -- and Change "1," to -- 11, --.
- Claim 22, line 1: Charge "compound" to -- method -- and /change "1, to -- 11, --.
- Claim 23, line 1: Change "compound" to -- method -- and Change "1," to -- 11, --.
- Change "1," to -- 11, --.

```
Claim 25, line 1: Charge "compound" to -- method -- and
                     to -- 11, --. الر1" to
                     Change "compound" to -- method -- and
Claim 26, line
                 1:
                     change "1," to -- 11, --.
                     Change "compound" to -- method --.
Claim 29, line
Claim 30, line
                    \prescript{\emptyset}hange "compound" to -- method --.
                     Change "compound" to -- method -- and
Claim 31, line
                 1:
                     \not {	t t} bange "1," to -- 11, --.
                 1: Change "compound" to -- method -- and
Claim 32, line
                     ¢hange "1," to -- 11, --.
```

33. (Amended.) A method according to claim 1, wherein said compound is of the formula



wherein

Z¹ is phenyl,

 Z^2 is H, and

is, in each case a hydrogen atom or a metal ion equivalent of an element of atomic number [21-25, 28, 29, 42, 44, 57-62, 64, and 66-83] 21-29, 42, 44 or 58-70, wherein at least two of the substituents X each represent a metal ion equivalent of atomic number 21-29, 42, 44 or 58-70,

or a physiologically acceptable salt thereof with an inorganic and or organic base, an amino acid or an amino acid amide.

Claim 34, line 1: Change "compound" to -- method --.

TA